Extension of Teletrial for Medicinal Cannabis Study in Advanced Cancer Patients

About

Torres and Cape HHS awarded a contract to Mater Misericordiae Ltd for the extension of a teletrial assessing the effect of medicinal cannabis (THC/CBD 1:20) on symptom scores in patients with advanced cancer.

The primary site, Mater Brisbane, is responsible for study conduct and patient management, while Torres and Cape HHS (TCHHS) acts as a satellite site, referring potential participants to the Principal Investigator at Mater, holding study drug for direct-to-patient collection, and supporting participants via telehealth appointments with the Teletrial Project Officer and Queensland Regional Clinical Trial Centre Study Coordinator.

TCHHS provides in-kind support for pharmacist time and a Teletrial Project Officer (0.1 FTE for 6 months), valued at $7,303.50, and is eligible for $700 per patient from the Australian Teletrial Program, estimated at $3,500.